CARB-X supports BioVersys in the fight against antimicrobial resistance with up to almost 9 million dollars
BioVersys receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies:
Webinar: the Basel-Stadt COVID-19 credit guarantee programme...
Boehringer Ingelheim to Acquire NBE-Therapeutics
«With innovation out of the antibiotics crisis» An contrib...
Cellestia Biotech launches new drug discovery program to tar...
BioVersys Announces First Subjects Dosed in Phase 1 Clinical...